Ranibizumab for Wet Age-Related Macular Degeneration
How Ranibizumab Treats Wet AMD
Ranibizumab is a VEGF-A inhibitor designed and engineered for intravitreal use inside the eye. According to the AAO, the FDA approved ranibizumab for wet AMD in June 2006, making it the first anti-VEGF therapy approved for this condition and transforming the standard of care. The medication is an antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), the protein that drives abnormal blood vessel growth and leaking beneath your retina.
By neutralizing VEGF-A, ranibizumab stops the growth of new abnormal vessels, reduces leaking from existing ones, and allows the fluid beneath your retina to absorb. According to the AAO, 80 to 90 percent of patients on anti-VEGF treatment stabilize or improve their vision.
Ranibizumab has been studied in some of the largest clinical trials in ophthalmology, establishing the evidence base that all subsequent anti-VEGF drugs have been measured against. The landmark CATT trial enrolled 1,208 patients across 44 U.S. centers and compared ranibizumab to bevacizumab on the same dosing schedules, according to NEI CATT results. Both drugs produced equivalent visual acuity gains when given on matching schedules. Monthly dosing produced slightly better outcomes at two years than as-needed dosing, with about half a line more of vision gained.
According to published dosing guidance, the standard ranibizumab dose is 0.5 mg delivered by intravitreal injection on a monthly schedule. The CATT trial confirmed that as-needed (PRN) dosing with monthly monitoring is an acceptable alternative for patients who prefer fewer injections. Your retina specialist may also use a treat-and-extend approach, extending the interval between injections step by step while monitoring OCT imaging, to find the longest safe interval that keeps your retina dry and your disease under control.
What Treatment Looks Like
According to the AAO and NEI, your doctor performs the injection in the office under topical anesthesia (numbing drops). Your doctor applies antiseptic to your eye surface and uses a lid holder to keep your eye open. A small needle delivers the medication into the vitreous cavity. Patients feel pressure but not sharp pain. Your vision may be blurry for several hours afterward, and you may notice mild redness or a gritty sensation for a day or two. Arrange a driver for the appointment since you will not be able to drive with blurry vision.
Most patients start with monthly injections. According to the NEI, treatment is long-term, and stopping without physician guidance can lead to vision loss from disease reactivation. Your retina specialist may keep you on monthly injections or transition to a treat-and-extend or PRN schedule based on your OCT imaging and visual acuity at each visit. Either way, regular monitoring remains essential because wet AMD can reactivate if VEGF suppression is insufficient. Consistent follow-up protects the visual gains you have achieved.
At each visit, your retina specialist checks your vision, performs OCT imaging, and evaluates your retina for fluid or vessel activity. Dry retina on OCT suggests the current schedule is working. Persistent or recurrent fluid may prompt your doctor to maintain monthly dosing, switch medications, or adjust the treatment approach. These imaging-guided decisions are the foundation of effective wet AMD management. Your doctor uses objective data from each scan rather than relying on vision changes alone, since fluid can return before you notice any difference in your sight.
Safety, Cost, and Alternatives
According to safety information, serious injection-related adverse events including endophthalmitis, retinal detachment, and traumatic cataract occur in fewer than 0.1 percent of injections. Common side effects include temporary blurred vision, mild eye discomfort, redness on the white of the eye, and floaters. These resolve within a few days without treatment. Your doctor checks your eye pressure after the injection before you leave the office.
According to the AAO, ranibizumab costs approximately $1,950 to $2,023 per dose, which is far more than compounded bevacizumab at about $64 per dose. Cost and insurance formulary placement are significant factors in treatment selection. Your retina specialist and their billing team can help you understand your out-of-pocket costs and explore alternatives if the price is a barrier. Many patients transition from ranibizumab to bevacizumab or a biosimilar for cost reasons while maintaining equivalent disease control.
According to Pharmacy Times (2025), multiple FDA-approved interchangeable ranibizumab biosimilars are now available. Biosimilars offer the same clinical benefit as the original medication and may reduce your costs. Your retina specialist can prescribe a biosimilar if one is available at your treatment center and covered by your plan. In states that permit it, a pharmacist can substitute an interchangeable biosimilar without a new prescription.
Questions About Ranibizumab Treatment
Both drugs target VEGF-A, but they are different molecules. Ranibizumab is an antibody fragment designed for intraocular use. Bevacizumab is a full-length antibody approved for cancer treatment and used off-label for wet AMD. The CATT trial showed equivalent visual outcomes when given on matching schedules. The main difference is cost: ranibizumab is approximately 30 times more expensive per dose.
Your retina specialist can switch you to aflibercept, faricimab, or bevacizumab based on your treatment response, injection frequency needs, or cost concerns. Switching anti-VEGF medications is common and safe. Your doctor monitors your response after any change.
Wet AMD is a chronic disease that requires ongoing treatment. Most patients need injections for years, and many receive them indefinitely. Your retina specialist works to find the longest safe interval between injections. Some patients on treat-and-extend protocols reduce their injection frequency over time, but stopping treatment risks disease reactivation.
Talk to your retina specialist about PRN or treat-and-extend dosing, which may reduce your visit frequency. Switching to a medication with longer dosing intervals, such as aflibercept or faricimab, is another option. Your doctor can tailor the treatment plan to your practical circumstances while maintaining disease control.
Medicare Part B covers anti-VEGF injections for wet AMD as physician-administered drugs. Commercial insurance coverage varies by plan and formulary. Some plans may prefer a different anti-VEGF agent or require prior authorization. Your doctor's office billing team can verify coverage, check prior authorization requirements, and estimate your out-of-pocket costs before your first injection.
FDA-approved biosimilars undergo rigorous testing to confirm they match the original medication in safety, efficacy, and quality. Your retina specialist would not recommend a biosimilar unless it met the same clinical standard as the original medication. Biosimilars may offer meaningful cost savings, particularly for patients with high copays or limited insurance coverage for branded anti-VEGF drugs. In states that permit pharmacist substitution, you may receive an interchangeable biosimilar automatically.
Keep Up With Your Treatment Schedule
Ranibizumab controls wet AMD by blocking the VEGF protein that drives your disease. Attend all scheduled injection and monitoring visits, and contact your retina specialist if you notice any vision changes between appointments.